{"id":"NCT00792103","sponsor":"NuPathe Inc.","briefTitle":"An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months","officialTitle":"An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2008-11-17","resultsPosted":"2013-05-07","lastUpdate":"2016-02-04"},"enrollment":198,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Disorders"],"interventions":[{"type":"DRUG","name":"NP101","otherNames":[]}],"arms":[{"label":"NP101","type":"EXPERIMENTAL"}],"summary":"The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by:\n\n* Subject self-examination skin irritation scores\n* Adverse events\n* Changes in vital signs and ECG parameters\n\nThe secondary objective is to evaluate the long term efficacy of NP101 as assessed by:\n\n* Headache pain free at two hours after patch activation for all initial acute migraine attacks treated with NP101\n* Headache pain relief at two hours after patch activation for all initial acute migraine attacks treated with NP101\n* Nausea free at two hours after patch activation for all initial acute migraine attacks treated with NP101\n* Phonophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101\n* Photophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101\n* Migraine free at two hours after patch activation for all initial acute migraine attacks treated with NP101\n\nThis study will use an open-label design to assess the long term safety of NP101 (sumatriptan iontophoretic transdermal patch).\n\nSubjects who continue to be in good health (use of a triptan or use of an NP101 patch is not contraindicated) and received treatment (patch activation) with the study patch for a qualifying migraine under study NP101-007 will be considered eligible for enrollment into the open-label study. Subjects will be expected to remain in the study for up to 12 months.","primaryOutcome":{"measure":"Subject Self-examination of Skin Irritation","timeFrame":"24 hours post patch activation","effectByArm":[{"arm":"NP101","deltaMin":1,"sd":0.96}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":["22352764"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":183},"commonTop":["Application site pruritus","Application Site Pain","Application site hypersensitivity"]}}